The Filing Desk

Cellectis vs Recursion Pharmaceuticals

Cellectis CLLS · Recursion Pharmaceuticals RXRX · Biotechnology

Recursion Pharmaceuticals reported revenue of $75 million in fiscal 2025, about the same as Cellectis' $73 million in fiscal 2025. Cellectis' revenue grew 75.8% in its latest year, and Recursion Pharmaceuticals' grew 26.9%. Cellectis had an operating margin of -45.3%, against -867.9% at Recursion Pharmaceuticals. Free cash flow was −$42 million at Cellectis and −$378 million at Recursion Pharmaceuticals.

Side by side

CellectisRecursion Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$73M$75M
Revenue growth75.8%26.9%
Revenue growth a year, last 5 years7.4%79.6%
Gross margin100.0%5.0%
Operating margin−45.3%−867.9%
Net margin−92.7%−863.4%
Free cash flow−$42M−$378M
Free cash flow margin−57.2%−506.5%
Return on capital—−117.2%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count10.7%63.2%
Last close$0.98$2.72
P/E at the last close——
Insider trades, last 12 months—sold $6.9 million
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CellectisRecursion Pharmaceuticals
Operating margin
Percent of revenue
CellectisRecursion Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CellectisRecursion Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cellectis and Recursion Pharmaceuticals pages.